- About Us
- Clinical Trials
Available Clinical Trials
- Resources
- Contact Us
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
GY020 is closed to accrual, effective August 29, 2022